New analysis from Frost & Sullivan (pharma.frost.com), Strategic Analysis of the Kenyan Diabetes Market, finds that the market earned revenues of $18.0 million in 2006 and estimates this to reach $26.8 million in 2012.
"The anti-diabetic pharmaceutical market in Kenya is benefiting from better access to healthcare delivery, drastic changes in lifestyle and a growing middle class," notes Frost & Sullivan Research Analyst Lizelle Wentzel. "More Kenyans are seeking treatment and being diagnosed with the disease."
The oral anti-diabetic market has grown considerably, bringing about a choice for patients between ethical or generic drugs as well as between prices. While the majority of drugs prescribed for diabetics are still oral, there are concerns about the glycaemic control abilities of these drugs, which may not be entirely efficient in bringing blood glucose levels down to the required levels.
The use of insulin, which is more expensive, is therefore being prescribed to type II diabetics to complement their oral drug treatment. In 2006, 43.0 per cent of type II diabetics were using insulin in addition to oral treatments. This trend will underpin the expansion of the market.
"The cost of treatment, especially for type II diabetics, is becoming more expensive," remarks Wentzel. "This is being exacerbated by the recent trend of complementing oral treatments with insulin so that the required glycaemic control can be attained."
Therefore, oral anti-diabetic drugs with tighter glycaemic control abilities and alternative methods of insulin delivery constitute a key market need. Companies able to fulfil this need stand to make strong gains. Manufacturers should try to lower costs, but simultaneously maintain a high level of quality.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the strategic analysis of the Kenyan diabetes market, then send an email to Patrick Cairns, Corporate Communications, at patrick.cairns[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by email.
Strategic Analysis of the Kenyan Diabetes Market is part of the Pharmaceutical and Clinical Diagnostics Growth Partnership Services Programme, which also includes research in the following markets: Diabetes Drug Delivery Methods—Market and Technologies, Emerging Therapies for Diabetes (Technical Insights), European Diabetes Market and South Korean Diabetes Diagnostics Markets. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.
Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership™ empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.
Strategic Analysis of the Kenyan Diabetes Market - M1F8